WESTERN-UNION-COMPANY
17.9.2020 15:02:34 CEST | Business Wire | Press release
Western Union, a leader in cross-border, cross-currency money movement and payments, announces a collaboration between its business division, Western Union Business Solutions , and Isabel Group , the leading provider of multi-bank services for both businesses and consumers and largest Fintech in Belgium.
As part of its partnership, Western Union Business Solutions will provide worldwide connectivity to Isabel Group’s multi-banking platform that enables organizations to manage their banking online and perform quick and easy payments. The Isabel 6 platform serves 70,000 professional user clients, and now collectively may access Western Union Business Solutions’ unrivaled global payment network across over 200 countries and territories in more than 130 currencies around the world. Western Union Business Solutions’ extensive global network, combined with knowledge of local markets, will help enable Isabel platform users to manage international payments simply, effectively, and efficiently. The expertise of Western Union Business Solutions’ foreign exchange specialists on currency fluctuation and foreign exchange markets will assist clients in managing international payments and foreign exchange risk through a wide range of hedging product offering.
Marc-Elie Caspar, country director France & Benelux at Western Union Business Solutions, notes:
“We are proud to extend and accelerate our presence and activities in Belgium through this key partnership with Isabel Group, the largest Fintech player offering the most popular B2B multi-banking ecosystem and online payment solution for companies of any size in Belgium. Together, we will offer our customers an innovative payment solution for foreign exchange transactions, dedicated customer support, negotiated rates and fees and an outstanding level of trust thanks to our European banking license.
“This type of partnership is part of our DNA at Western Union Business Solutions. We equip and support organizations around the world that are looking for a partner to optimize cross-border payments with solutions for sending, receiving, and managing international payments.”
The Isabel 6 platform is backed by the expertise, resources and technology provided by Isabel Group. The Belgian fintech has an extensive network of partners and is one of the three companies in Belgium (source: AMPG) to meet the requirements of the ISO/IEC 20000-1 2011 standard and to have obtained the certification corresponding to this standard.
Jean de Crane, CEO at Isabel Group, adds: “We are happy to welcome Western Union Business Solutions as a new international member on the Isabel 6 multi-banking platform. This collaboration will add value to our mutual business customers in the processing of their payments and foreign exchange strategies. We are looking forward to working together with this international player in our ecosystem.”
About Western Union
The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Our omnichannel platform connects the digital and physical worlds and makes it possible for consumers and businesses to send and receive money and make payments with speed, ease, and reliability. As of June 30, 2020, our network included over 550,000 retail agent locations offering our branded services in more than 200 countries and territories, with the capability to send money to billions of accounts. Additionally, westernunion.com, our fastest growing channel in 2019, is available in over 75 countries, plus additional territories, to move money around the world. With our global reach, Western Union moves money for better, connecting family, friends, and businesses to enable financial inclusion and support economic growth. For more information, visit www.westernunion.com .
About Isabel Group
Isabel Group links and streamlines the administrative and financial processes of businesses. The financial services provider ensures a smooth and reliable exchange of documents, payments, and identities, and automates access to them. This helps businesses to gain insight into their financial flows and make better business decisions.
Some 65,000 businesses, 3,000 accounting firms, 150 software partners, and 30 banks are working with or linked to Isabel Group’s software: Isabel 6, Seven, Ibanity, CodaBox, ClearFacts, Ponto, BookMate, SignHere, KUBE and Zoomit. This means that Isabel Group is managing Belgium’s most extensive financial infrastructure. With more than 300 experts, the group automates 450 million transactions per year or 7.10 billion euros per day.
WU-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20200917005169/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
